Diastole

Windtree Therapeutics Announces Issuance of New Istaroxime Patent from U.S. Patent and Trademark Office

Retrieved on: 
Friday, February 24, 2023

Istaroxime is an investigational drug candidate being studied in early cardiogenic shock and acute heart failure.

Key Points: 
  • Istaroxime is an investigational drug candidate being studied in early cardiogenic shock and acute heart failure.
  • The claims of the newly issued patent cover longer durations of istaroxime infusion for improved outcomes in treatment of acute heart failure.
  • “Windtree continues to strengthen the patent estate for istaroxime with this new issuance from the USPTO,” said Craig Fraser, CEO and President of Windtree Therapeutics.
  • We plan to continue this work to further expand istaroxime’s patent estate in the clinical development work ahead.”

BlueStar Reduces Systolic Blood Pressure in 42% of Patients in Remote Patient Monitoring Program Using Cellular-Enabled Blood Pressure Monitors

Retrieved on: 
Thursday, February 9, 2023

As part of an 18-week Remote Patient Monitoring program, 42% of the 524 FQHC patients with AHA Stage II Hypertension had their Hypertension “controlled” within 10 weeks, with an average drop in Systolic Blood Pressure of 16 mmHG.

Key Points: 
  • As part of an 18-week Remote Patient Monitoring program, 42% of the 524 FQHC patients with AHA Stage II Hypertension had their Hypertension “controlled” within 10 weeks, with an average drop in Systolic Blood Pressure of 16 mmHG.
  • BlueStar enrolled patients, shipped equipment, and monitored the patient populations over the 18-week period.
  • All of the patients who participated in the program were provided a cellular-connected iBloodPressure® monitoring device from Smart Meter to help monitor their blood pressure at home.
  • The ease of use supports improved patient adherence to care plan instructions leading to improved outcomes and higher patient satisfaction.

Windtree Announces Notice of Allowance from the US Patent and Trademark Office for a New Istaroxime Patent

Retrieved on: 
Tuesday, October 25, 2022

A notice of allowance is issued by the USPTO to indicate that the application has passed examination.

Key Points: 
  • A notice of allowance is issued by the USPTO to indicate that the application has passed examination.
  • Istaroxime is an investigational drug candidate being studied in early cardiogenic shock and acute heart failure.
  • The U.S. Patent, titled: Istaroxime-Containing Intravenous Formulation for the Treatment of Acute Heart Failure (AHF), is a continuing patent application of the expedited U.S. Track One filing by Windtree, which resulted in U.S. Patent No.
  • We are pleased with this notice of allowance for a new patent that will continue to strengthen the istaroxime patent estate, said Craig Fraser, President and Chief Executive Officer of Windtree.

 Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

Retrieved on: 
Friday, September 30, 2022

Further, efficacy data from the pediatric patients are following similar or more favorable positive trends as in the adults at a similar timeframe.

Key Points: 
  • Further, efficacy data from the pediatric patients are following similar or more favorable positive trends as in the adults at a similar timeframe.
  • RP-A501 is an investigational gene therapy product being developed for Danon Disease and the first potential gene therapy for monogenic heart failure.
  • Rockets first clinical program using adeno-associated virus (AAV)-based gene therapy is for Danon Disease, a devastating, pediatric heart failure condition.
  • Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes.

China Nicorandil Market Research Report 2022: Sales 2017-2021, Major Manufacturers 2017-2021, Sales Prices 2021-2022, Future Prospects 2022-2031 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 8, 2022

The "Research Report on China's Nicorandil Market, 2022-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Nicorandil Market, 2022-2031" report has been added to ResearchAndMarkets.com's offering.
  • The analyst survey data show that from 2017 to 2021, the sales value of nicorandil in the Chinese market kept increasing year by year.
  • The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.
  • The rising number of patients with coronary heart disease in China has contributed to the growth of the related drug market.

China Nicorandil Market Research Report 2021: Sales 2016-2020, Major Manufacturers, Prices 2020-2021, Prospects 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 10, 2022

The "Research Report on China's Nicorandil Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Research Report on China's Nicorandil Market, 2021-2025" report has been added to ResearchAndMarkets.com's offering.
  • The rising number of patients with coronary heart disease in China has contributed to the growth of the market.
  • The publisher's survey data show that from 2016 to 2020, the sales value of nicorandil in the Chinese market kept increasing year by year.
  • The dosage forms of nicorandil sold in China include tablets and injection, with the latter already occupying the major market share in terms of sales value.

Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure

Retrieved on: 
Tuesday, October 20, 2020

Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicells lead therapeutic, Zofin, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF.

Key Points: 
  • Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicells lead therapeutic, Zofin, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF.
  • HFpEF, or diastolic heart failure , is a complex inflammatory disease in which the heart is unable to receive and pump adequate blood to meet the bodys needs.
  • RCN, under the leadership of its Medical Director, Dr. Vincent Friedewald, has extensive experience in managing patients with all forms of heart failure, including the large and growing population of patients with HFpEF.
  • Organicell has no intention and specifically disclaims any duty to update the information in this press release.

Analytics 4 Life® Presents Early Data Supporting Novel, Non-Invasive Method of Predicting Elevated Left Ventricular Pressure at the American College of Cardiology’s (ACC) 69th Annual Scientific Session Together with World Congress of Cardiology

Retrieved on: 
Monday, March 30, 2020

The data suggest that a machine-learned approach performs highly in predicting elevated left ventricular end-diastolic pressure (LVEDP) and could potentially serve as a novel, non-invasive diagnostic for identifying patients with elevated filling pressures at point-of-care.

Key Points: 
  • The data suggest that a machine-learned approach performs highly in predicting elevated left ventricular end-diastolic pressure (LVEDP) and could potentially serve as a novel, non-invasive diagnostic for identifying patients with elevated filling pressures at point-of-care.
  • Details of the poster presentation at the ACC.20 Virtual Session is as follows:
    The presentation can be viewed here.
  • The CorVista System is a non-invasive cardiac diagnostic platform to diagnose heart disease point-of-care without radiation or cardiac stress.
  • Analytics 4 Life is combining digital health and machine learning to develop a novel, non-invasive cardiac diagnostic modality.

Livongo Study Demonstrates Sustained Blood Pressure Reduction for People Living with Both Diabetes and Hypertension Outside Traditional Care Settings

Retrieved on: 
Thursday, November 14, 2019

In addition, Livongo Members who checked their blood pressure more frequently using Livongos connected blood pressure monitoring technology experienced additional improvement for both systolic blood pressure (the top number of a blood-pressure reading) and diastolic blood pressure reduction (the bottom number of a blood-pressure reading).

Key Points: 
  • In addition, Livongo Members who checked their blood pressure more frequently using Livongos connected blood pressure monitoring technology experienced additional improvement for both systolic blood pressure (the top number of a blood-pressure reading) and diastolic blood pressure reduction (the bottom number of a blood-pressure reading).
  • Without continued support, many people with high blood pressure do not understand how behavioral and lifestyle changes affect their blood pressure.
  • Multivariable regression analysis identified that age, baseline blood pressure, and frequency of blood pressure readings were associated with a reduction in blood pressure.
  • All participants received a Livongo for Hypertension blood pressure monitor and cuff that connected wirelessly with Livongos smartphone app.

Corvia Medical's Interatrial Shunt Device (IASD®) Receives Breakthrough Device Designation For Heart Failure

Retrieved on: 
Wednesday, October 9, 2019

TEWKSBURY, Mass., Oct. 9, 2019 /PRNewswire/ -- Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its InterAtrial Shunt Device (IASD) for heart failure.

Key Points: 
  • TEWKSBURY, Mass., Oct. 9, 2019 /PRNewswire/ -- Corvia Medical, Inc., a privately-held company with a first-in-class structural heart device to treat heart failure, today announced the US Food and Drug Administration (FDA) has granted the company a Breakthrough Device designation for its InterAtrial Shunt Device (IASD) for heart failure.
  • "Receiving Breakthrough Device designation from the FDA underscores the significant unmet need for more effective treatment options for heart failure patients," commented George Fazio, President and CEO of Corvia Medical.
  • There are two types of heart failure: heart failure with reduced ejection fraction (HFrEF), also called systolic heart failure, and heart failure with preserved or midrange ejection fraction (HFpEF/HFmrEF), previously called diastolic heart failure.
  • The InterAtrial Shunt Device is the world's first transcatheter device to treat heart failure with preserved (HFpEF) or mid-range ejection fraction (HFmrEF).